Literature DB >> 15036653

Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma.

Kaori Tsuboi1, Tatsuya Miyazaki, Masanobu Nakajima, Yasuyuki Fukai, Norihiro Masuda, Ryokuhei Manda, Minoru Fukuchi, Hiroyuki Kato, Hiroyuki Kuwano.   

Abstract

Interleukin (IL)-12 and IL-18 participate in tumor immunology. Serum IL-12 and IL-18 levels were determined in patients with esophageal carcinoma, and the relationship between clinicopathologic factors and prognosis was investigated. Peripheral blood samples were obtained from 15 healthy volunteers and from 70 patients with esophageal carcinoma before curative surgery. IL-12 and IL-18 levels were determined in each serum sample by enzyme-linked immunosorbent assay. Mean serum IL-12 and IL-18 levels were significantly higher in patients with esophageal carcinoma compared with healthy volunteers (P < 0.05) and mean serum IL-12 and IL-18 levels increased in patients as the pathologic stage progressed. A positive correlation was observed between serum IL-12 and IL-18 levels (P < 0.01). In patients with esophageal carcinoma, increasing serum IL-12 and IL-18 levels correlated with tumor growth and progression. The function of these two interleukin in the host immune response remains unclear. However, this part of the host immune response did not appear to contribute to the postoperative prognosis. Serum IL-12 and IL-18 levels might correlate with a certain depth of invasion and might be useful tumor markers in patients with esophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036653     DOI: 10.1016/j.canlet.2003.10.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  The -137G>C polymorphism in interleukin-18 promoter region and cancer risk: evidence from a meta-analysis of 21 studies.

Authors:  Tie-Jun Liang; Hui Ma; Cong-Xiao Wang; Yin-Rong Liu; Xing-Guo Wang
Journal:  Tumour Biol       Date:  2013-06-22

Review 2.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

3.  Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma.

Authors:  Giang Huong Nguyen; Aaron J Schetter; David B Chou; Elise D Bowman; Ronghua Zhao; Jason E Hawkes; Ewy A Mathé; Kensuke Kumamoto; Yiqiang Zhao; Anuradha Budhu; Nobutoshi Hagiwara; Xin Wei Wang; Masao Miyashita; Alan G Casson; Curtis C Harris
Journal:  Clin Cancer Res       Date:  2010-10-14       Impact factor: 12.531

4.  Interleukin-18 gene promoter and serum level in women with ovarian cancer.

Authors:  Alamtaj Samsami Dehaghani; Khatere Shahriary; Mohammad Amin Kashef; Sirous Naeimi; Mohammad Javad Fattahi; Zahra Mojtahedi; Abbas Ghaderi
Journal:  Mol Biol Rep       Date:  2009-03-05       Impact factor: 2.316

5.  Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma.

Authors:  Pisit Tangkijvanich; Duangporn Thong-Ngam; Varocha Mahachai; Apiradee Theamboonlers; Yong Poovorawan
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

6.  Tobacco exposure may enhance inflammation in prostate carcinoma patients: an explorative study in north Indian population.

Authors:  Shailendra Dwivedi; Apul Goel; Anil Mandhani; Sanjay Khattri; Kamlesh Kumar Pant
Journal:  Toxicol Int       Date:  2012-09

7.  Association of interleukin-18 gene promoter -607 C>A and -137G>C polymorphisms with cancer risk: a meta-analysis of 26 studies.

Authors:  Xin Yang; Man-Tang Qiu; Jing-Wen Hu; Feng Jiang; Ming Li; Jie Wang; Qin Zhang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

8.  The -607C/A polymorphisms in interleukin-18 gene promoter contributes to cancer risk: evidence from a meta-analysis of 22 case-control studies.

Authors:  Ming Wang; Xiao-Yang Zhu; Liang Wang; Yu Lin
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

9.  TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.

Authors:  Shinji Miwa; Hideji Nishida; Yoshikazu Tanzawa; Munetomo Takata; Akihiko Takeuchi; Norio Yamamoto; Toshiharu Shirai; Katsuhiro Hayashi; Hiroaki Kimura; Kentaro Igarashi; Eishiro Mizukoshi; Yasunari Nakamoto; Shuichi Kaneko; Hiroyuki Tsuchiya
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

10.  Intracellular distributing and interferon-γ secretion of human interleukin-18 in BxPC-3 cells.

Authors:  Jin Yang; Linlin Chen; Bin Xu; Jian Xu; Jinquan Sun; Wen Shen; Ting Zhang
Journal:  Int J Med Sci       Date:  2014-01-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.